safety and efficacy of a cldn18.2-specific car t-cell therapy in gi adenocarcinoma
Published 2 years ago • 393 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
0:34
expanding indications for a cldn18.2-specific car t-cell therapy in gi cancers
-
0:55
future directions for cldn18.2-specific car t-cell therapy in gi cancers
-
2:01
salvage ct041 cldn18.2-specific car t-cell therapy for patients with advanced gi malignancies
-
0:58
lb1908: a novel car-t cell therapy targeting claudin 18.2 in gi malignancies
-
2:53
safety and efficacy of allogenic car-t cell treatment
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
1:04
what does the future hold for car-t cells in gastric cancers?
-
4:55
dan's story: car t-cell therapy treatment for lymphoma
-
1:35
assessing the prevalence of cldn18.2 in gastric/gastroesophageal cancers
-
1:07
claudin 18.2: a biomarker for gastric cancer
-
3:48
epcam-targeted car t-cell therapy for advanced colorectal and gastric tumors
-
2:17
claudin 18.2 and fgfr2b as novel targets in gastric cancer
-
1:59
car-t therapy for previously treated solid tumors in the digestive tract
-
2:49
spotlight: zolbetuximab and m-folfox6 in cldn18.2 , her2- gej cancer
-
2:08
targeting cldn18.2 with zolbetuximab in gastric and gej cancer
-
1:00
evaluating the emerging role of cellular therapies in gi cancers
-
1:26
the safety and efficacy of allosct following car-t cell therapy for large b-cell lymphoma
-
1:53
the application of car t-cell therapy for solid tumors
-
3:43
safety and efficacy of rapcabtagene autoleucel (ytb323), a car t-cell therapy, in r/r dlbcl